Microalbuminuria is a strong predictor of renal and cardiovascular risk in diabetes, and screening combined with ACE inhibitor therapy is beneficial for retarding renal disease progression.
No takes yet. Share an insight, caveat, or question.
Supports microalbuminuria screening and ACE inhibitor use in diabetes; confirms consensus on renal and CV risk prediction.
McKenna et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: